GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Sales GSK Plc’s leading vaccines sank in the third quarter after the British drugmaker was hit by limited access to the shots ...

GSK GSK1.94%increase; green up pointing triangle cut its full ... a setback for the company’s efforts to bolster its vaccines ...

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

BRENTFORD, Britain — BRENTFORD, Britain — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of 4 cents ...